ZBH · US market
ZIMMER BIOMET HOLDINGS
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$16.80bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- US$806.70m
- Latest-quarter run-rate earnings
- US$793.20m
- Latest fiscal-year earnings
- US$705.10m
- Trailing revenue
- US$8.51bn
- Latest-quarter run-rate revenue
- US$8.71bn
- Latest fiscal-year revenue
- US$8.23bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- MVAL · VanEck Morningstar Wide Moat Value ETF4.22% weight · Holdings dated 30 June 2026
- IHI · iShares U.S. Medical Devices ETF2.64% weight · Holdings dated 19 August 2026
- OAKM · Oakmark U.S. Large Cap ETF2.49% weight · Holdings dated 30 June 2026
- MWMZX · VanEck Morningstar Wide Moat Fund Class Z2.30% weight · Holdings dated 30 June 2026
- MOAT · VanEck Morningstar Wide Moat ETF2.30% weight · Holdings dated 30 June 2026
- NEFOX · Natixis Funds Trust II Oakmark Fund Class A2.05% weight · Holdings dated 30 June 2026
- CVFCX · Victory Pioneer Disciplined Value Class A2.03% weight · Holdings dated 31 May 2026
- FXH · First Trust Health Care AlphaDEX Fund1.97% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
- MOTG · VanEck Morningstar Global Wide Moat ETF1.89% weight · Holdings dated 30 June 2026
- MDEV · First Trust Indxx Medical Devices ETF1.89% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.